Pharmacological cancer treatment and venous thromboembolism risk

16Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Risk factors for cancer-associated thrombosis are commonly divided into three categories: patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in cancer treatment. Chemotherapy has been identified as an independent risk factor for venous thromboembolism (VTE). However, it should be noted, that the risk of VTE is not consistent among all cytotoxic agents. In addition, different supportive care drugs, such as erythropoiesis stimulating agents or granulocyte colony stimulating factors, and hormonotherapy have been associated to an increased risk of VTE. Immunotherapy and molecular-targeted therapies have significantly changed the treatment of cancer over the past decade. The main subtypes include tyrosine-kinase inhibitors, monoclonal antibodies, small molecules, and immunomodulatory agents. The relationship between VTE and targeted therapies remains largely unknown.

Cite

CITATION STYLE

APA

Muñoz Martín, A. J., Ramírez, S. P., Morán, L. O., Zamorano, M. R., Benéitez, M. C. V., Salcedo, I. A., … Fernández, J. M. S. (2020). Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal, Supplement, 22, C2–C14. https://doi.org/10.1093/EURHEARTJ/SUAA004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free